Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
Journal: Journal of clinical pharmacology
Published: August 13, 2025
Proposing a framework to quantify the potential impact of pharmacokinetic drug-drug interactions caused by a new drug candidate by using real world data about the target patient population.
Journal: Clinical and translational science
Published: October 13, 2023
Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.
Journal: CPT: pharmacometrics & systems pharmacology
Published: July 18, 2023
A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 07, 2023
Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Journal: Journal of clinical pharmacology
Published: May 03, 2021
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Journal: Journal of clinical pharmacology
Published: October 27, 2020
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: September 19, 2019
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices.
Journal: Clinical pharmacology in drug development
Published: September 22, 2017
Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].
Journal: Cardiovascular therapeutics
Published: February 08, 2017
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
Journal: The American journal of cardiology
Published: November 04, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026